Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metformin Plus Irinotecan for Refractory Colorectal Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2014 by Barretos Cancer Hospital
Information provided by (Responsible Party):
Barretos Cancer Hospital Identifier:
First received: August 26, 2013
Last updated: April 17, 2014
Last verified: April 2014

MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.

Condition Intervention Phase
Colorectal Neoplasms
Drug: Metformin
Drug: Irinotecan
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Barretos Cancer Hospital:

Primary Outcome Measures:
  • Non-Progression at week 12th of treatment [ Time Frame: 12th week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: 12th week ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: 12th week ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: 12th week ] [ Designated as safety issue: No ]
    Measured by EORTC QLQ C30

  • Safety [ Time Frame: 12th week ] [ Designated as safety issue: Yes ]
    Assessment of toxicity according to CTC 4.0

Estimated Enrollment: 41
Study Start Date: April 2014
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metfomin + irinotecan
Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
Drug: Metformin
metformin up to 2500mg/d
Drug: Irinotecan
Irinotecan 350 mg/m² IV q21d

Detailed Description:

MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and anti-EGFr antibody if Kras wild type.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older
  • Biopsy-proven colorectal adenocarcinoma
  • Ineligibility for curative intent therapy, e.g., surgery or radiation
  • Disease progression after oxaliplatin (either adjuvant or palliative), fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a anti-EGFR therapy
  • Assessable disease according to RECIST v1.1

Exclusion Criteria:

  • known hypersensitivity to metformin or irinotecan
  • SNC metastasis
  • Acute or chronic severe infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01930864

Contact: Joao Paulo SN Lima, MD 551733216600 ext 7128
Contact: Arinilda C Bragagnoli, MD 551733216600 ext 6829

Barretos Cancer Hospital Recruiting
Barretos, SP, Brazil, 14784-400
Contact: Joao Paulo SN Lima, MD    551733216600 ext 7128   
Contact: Arinilda C Bragagnoli, MD    551733216600 ext 6829   
Principal Investigator: Joao Paulo SN Lima, MD, PhD         
State University of Campinas Not yet recruiting
Campinas, São Paulo, Brazil, 1300000
Contact: Lígia T Macedo, MD   
Principal Investigator: Ligia T Macedo, MD         
Sponsors and Collaborators
Barretos Cancer Hospital
Principal Investigator: Joao Paulo SN Lima, MD, PhD Barretos Cancer Hospital
  More Information

No publications provided

Responsible Party: Barretos Cancer Hospital Identifier: NCT01930864     History of Changes
Other Study ID Numbers: MetIri
Study First Received: August 26, 2013
Last Updated: April 17, 2014
Health Authority: Brazil: Ethics Committee

Keywords provided by Barretos Cancer Hospital:
colorectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors processed this record on February 27, 2015